RT Journal Article
SR Electronic
T1 A comparison of treatment regimens for autoimmune hemolytic anemia: A network meta-analysis protocol
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.01.31.20019968
DO 10.1101/2020.01.31.20019968
A1 Jiawen Deng
YR 2020
UL http://medrxiv.org/content/early/2020/02/04/2020.01.31.20019968.abstract
AB Autoimmune hemolytic anemia (AIHA) is a rare blood disorder that result in the hemolysis of red blood cells (RBCs) due to the presence of autoantibodies in the serum. There are a variety of treatment regimens available for AIHA, including glucocorticoids, monoclonal antibody rituximab and splenectomy. We propose a network meta-analysis that investigates whether the use of different regimens can decrease adverse events, increase remission rate and improve lab results, including hemoglobin, RBC, reticulocyte counts, hematocrit and total bilirubin.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding received.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo data available for this protocol.